Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2008 Jul;7(7):2192–2202. doi: 10.1158/1535-7163.MCT-08-0333

Figure 2.

Figure 2

(-)-Gossypol enhances the chemotherapy of docetaxel in human prostate cancer PC-3 cells. A. MTT-based cell viability assay of (-)-gossypol docetaxel in PC-3. B. IC50 isobologram of the combination treatments. In the isobologram, a plot on the diagonal line indicates that the combination is simply additive. A plot to the left under the line indicates that the combination is synergistic, whereas a plot to the right above the line indicates that it is antagonistic. CI (combination index) < 1 is considered synergistic of the combination treatment (20). C, D. Western blot analysis showed the effect of docetaxel and (-)-gossypol on proteins expression in PC-3 cells. Cells were treatment with docetaxel and (-)-gossypol of the indicated doses for 24 hours (C) or 48 hours (D), then collected for Western blot (60μg/lane). Data with (-)-gossypol 10 μM treatment for 48 hours were not shown because of severe cell death.